

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



November 4, 2025

To whom it may concern:

Company name KISSEI PHARMACEUTICAL CO., LTD.
Representative Mutsuo Kanzawa, Chairman and CEO
(Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact Takahide Kitahara, Managing Director,
Department Manager of Corporate Finance
and Management Department, CFO
(Telephone +81-263-25-9081)

Notice Concerning Revisions to Financial Results Forecast

In light of the recent trends in financial results and other factors, KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that it has revised the financial results forecast for the fiscal year ending March 31, 2026 announced on July 29, 2025 as follows.

Revisions to the Financial Results Forecast

Revisions to the Consolidated Financial Results Forecast Figures for the Fiscal Year Ending March 31, 2026
(April 1, 2025 - March 31, 2026)

| | Net sales | Operating profit | Ordinary profit | Profit attributable to owners of parent | Basic earnings per share |
|---|-----------------------|------------------------|------------------------|---|--------------------------|
| Previously announced forecast (A) | Million yen 91,500 | Million yen (4,000) | Million yen (2,600) | Million yen 12,300 | Yen 297.07 |
| Revised forecast (B) | 95,500 | (2,600) | (1,100) | 12,700 | 305.56 |
| Change (B - A) | 4,000 | 1,400 | 1,500 | 400 | |
| Change rate (%) | 4.4 | — | — | 3.3 | |
| (Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025) | 88,330 | 5,773 | 6,974 | 11,961 | 274.21 |

Reasons for the Revision

As a result of a review taking the financial results for the six months ended September 30, 2025 and the current business environment into consideration, the Company expects an increase of ¥2,500 million in the pharmaceutical business and ¥1,500 million in other businesses, resulting in a total sales forecast of ¥95,500 million (an increase of ¥4,000 million).

Regarding profits, in addition to the results for the six months ended September 30, 2025, while the cost of sales

ratio is expected to rise in the latter half of the fiscal year, net sales are projected to increase. Therefore, the profit forecast for the fiscal year ending March 31,2026 is as follows: operating profit is expected to improve by ¥1,400 million from the initial forecast to a loss of ¥2,600 million. and ordinary income is expected to improve by ¥1,500 million from the initial forecast to a loss of ¥1,100 million. Meanwhile, profit attributable to owners of parent is expected to increase by ¥400 million from the initial forecast to ¥12,700 million.

(Note) The forecasts above are based on information available to the Company as of the date of publication of this document and certain assumptions as of the date of publication of this document on uncertainties that may affect future financial results. Actual results may differ greatly from these forecasts due to a variety of factors in the future.

-End-